Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | TACR1 | P25103 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.42 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.42 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.42 |
| ▸ | PSMD3 | O43242 | 1/20 | 0.42 |
| ▸ | PSMC3 | P17980 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15576811 | 0.89 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL6068726 | 0.89 | CA1 (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL11761286 | 0.89 | CA1 (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL6068730 | 0.89 | CA1 (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL21848157 | 0.87 | TSHR (0.67) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL13246023 | 0.86 | TSHR (0.45) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL14629715 | 0.86 | ALDH1A1 (0.51) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL18391961 | 0.84 | CA1 (0.46) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL10760744 | 0.83 | PRSS1 (0.54) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL13652227 | 0.83 | TSHR (0.42) | TSHRCA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143231-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | JANSSEN BIOTECH, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20110059939-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN ,INC (US) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059939-A1 | THERAPEUTIC COMPOUNDS | CYP11B1, CYP11B2, SLC10A2 | TSHR 4649/4885CA1 2489/4885CA2 457/4885 |
| US-20220143231-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BDNF, CD47, MAG | TSHR 1143/4885CA1 77/4885CA2 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.